Registry for patients with secondary central nervous system lymphoma
Non-interventional, Prospective Observational Study of the Treatment Practice of CNS Involvement of Malignant Lymphoma in Routine Clinical Practice
This study is collecting information from patients with secondary central nervous system lymphoma to see how different treatments work and what side effects they might cause.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Sex | All |
| Sponsor | Charite University, Berlin, Germany Academic / other |
| Locations | 1 site (Berlin) |
| Trial ID | NCT05114330 on ClinicalTrials.gov |
What this trial studies
This observational registry aims to collect and document data on treatment strategies for secondary central nervous system lymphoma (SCNSL) in routine clinical practice. It will gather information on therapeutic approaches, clinical outcomes, and the frequency of serious adverse events associated with various treatment options. The study will involve participation from inpatient and outpatient clinics, as well as private oncology practices, with data compiled by the Charité - CNS Lymphoma Working Group. All patients with SCNSL will be included, regardless of their treatment stage or regimen.
Who should consider this trial
Good fit: Ideal candidates for this registry are all patients diagnosed with secondary central nervous system lymphoma, regardless of their treatment history.
Not a fit: Patients who do not have a diagnosis of secondary central nervous system lymphoma will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of effective treatment strategies for SCNSL, potentially improving patient outcomes.
How similar studies have performed: Other observational studies have successfully documented treatment outcomes in similar patient populations, indicating that this approach is both valid and valuable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • All patients with SCNSL can and should be included in the registry regardless of which treatment options are used and whether the treatment being given is first-line, recurrence, or maintenance therapy for SCNSL. Exclusion Criteria: • None
Where this trial is running
Berlin
- Charité - Universitätsmedizin, Med. Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie (CBF) — Berlin, Germany (Recruiting)
Study contacts
- Study coordinator: Stefan Habringer, MD
- Email: stefan.habringer@charite.de
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.